


#214



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: Aza- and Polyaza-Napthalenyl Carboxamides
Useful as HIV Integrase Inhibitors

Art Unit: 1614

Examiner: To Be Assigned

DOCKETED
JAN 10 2002
BARBARA REAssistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97RECEIVED
AUG 12 2003
TECH CENTER 1600/2900

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By [Signature] Date 1-10-2002

INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3462

Date: January 10, 2002



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY <i>Kenneth R. Walton</i>	DATE <i>1-10-2002</i>
CASE NUMBER/ <i>20157Y</i>	SERIAL NUMBER <i>09/973,853</i>
DATE FILED <i>October 10, 2001</i>	
APPLICANT <i>Anthony et al.</i>	
EXPRESS MAIL NO.	

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET





P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

1-11-2002

CASE NUMBER

20757Y

SERIAL NUMBER

091973,853

DATE FILED

October 10, 2001


APPLICANT

Anthony et al.

EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

1-11-2002

CASE NUMBER

20757Y

SERIAL NUMBER

09/973,853

DATE FILED

October 10, 2001

APPLICANT


Anthony et al.


EXPRESS MAIL NO.

RECEIVED
FEB 05 2002
P&T

The Patent & Trademark Office acknowledges and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: Aza- and Polyaza-Napthalenyl Carboxamides
Useful as HIV Integrase Inhibitors

Art Unit: 1614

Examiner: To Be Assigned

RECEIVED
AUG 12 2003
TECH CENTER 1600/2000Assistant Commissioner for Patents
Washington, D.C. 20231JOCKETE
FEB 4 2002
RBARA REINFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By 

Date

2-4-2002

INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.


Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3462

Date: February 4, 2002



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY <i>Kenneth R. Walston</i>	DATE <i>2-4-2002</i>
CASE NUMBER/ <i>20157Y</i>	SERIAL NUMBER <i>09/913,853</i>
DATE FILED <i>October 10, 2001</i>	
APPLICANT <i>Anthony et al.</i>	
EXPRESS MAIL NO. <i>RBARA RE</i>	

JOCKETE
FEB 26 2002

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☒ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET





RECEIVED D/F

AUG 12 2003

TECH CENTER 1000/1000
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Anthony et al.
Serial No.:	09/973,853
Docket No.:	20757Y
Filed:	October 10, 2001
For:	AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS INTEGRASE INHIBITORS

Art Unit:

1614

Examiner:

Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached form is a citation to a patent document, a copy of which is enclosed. The submission and listing of this reference is not to be construed as an admission that the reference is "prior art" with respect to the claimed invention. In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In addition, in accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

It is requested that the Examiner consider the cited reference as part of the examination of the subject application, make the reference of record, and return an initialed copy of the attached form with the next communication to Applicants.

This statement is being filed more than three months after the filing date but prior to a first Official Action on the merits. Accordingly, no fee is due. In the event a first Official Action on the merits has already been mailed, but has not yet been received, it is still believed that no fee is due, because the undersigned certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By David Hookes Date 7/10/02
MERCK & CO., INC.

Respectfully submitted,

By Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: July 10, 2002



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

7-10-2002

CASE NUMBER/

20757Y

SERIAL NUMBER

09/973,853

DATE FILED

October 10, 2001


APPLICANT

Neville J. Anthony, et al.

EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES (att. 1 ref.)
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



D/F
RECEIVED

AUG 12 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicants: Anthony, et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: AZA- AND POLYAZA-NAPHTHALENYL
CARBOXAMIDES USEFUL AS INTEGRASE
INHIBITORS

Art Unit: 1614

Examiner: Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

DOCKETED

FEB 10 2003

LORI SCHEPISI

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.


3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT February 10, 2003
EXPRESS MAIL NO. EL 920633426 US
 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
 BEING DEPOSITED WITH THE UNITED STATES POSTAL
 SERVICE AS EXPRESS MAIL "POST OFFICE TO
 ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
 AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
 FOR PATENTS, WASHINGTON, D.C. 20231.
 MAILED BY Lori Schepisi
 DATE 2-10-03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By _____ Date _____



INFORMATION DISCLOSURE STATEMENT

4. Except for Cite Nos. _____, copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907


(732)594- 3462

Date: February 10, 2003




P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY Kenneth R. Walton		DATE 2-10-2003
CASE NUMBER/ 20757Y	SERIAL NUMBER 09/973,853	
DATE FILED October 10, 2001		
APPLICANT Anthony, et al.		
EXPRESS MAIL NO. EL 920633426 US		



The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES (att. 4 refs.)
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



RECEIVED
AUG 12 2003
TECH CENTER 150123

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

2-12-2003

CASE NUMBER/

20757Y

SERIAL NUMBER

09/973,853

DATE FILED

October 10, 2001

APPLICANT

Anthony et al.

EXPRESS MAIL NO.

EL 920762522 US

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



F4424

EXHIBIT 7



PATENT Case No. 20757

RECEIVED

AUG 12 2003

TECH CENTER 1003/2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Anthony et al.

Serial No. 09/973,853

Art Unit: 1614

Filed: October 10, 2001

Examiner: Not Yet Assigned

For: AZA- AND POLYAZA-NAPHTHALENYL
CARBOXAMIDES USEFUL AS INTEGRASE
INHIBITORS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

FEB 25 2003

INFORMATION DISCLOSURE STATEMENT FOR SCHEPISI
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT February 24, 2003
EXPRESS MAIL NO. EL 920762575 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY Mr. Schepisi
FEB 24/03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By

Date

INFORMATION DISCLOSURE STATEMENT

4. Except for Cite Nos. _____, copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000


Rahway, N.J. 07065-0907

(732)594- 3462

Date: February 24, 2003



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY Kenneth R. Walton		DATE 2-24-2003
CASE NUMBER/ 20757Y	SERIAL NUMBER 09/973,853	
DATE FILED October 10, 2001		
APPLICANT Anthony et al.		
EXPRESS MAIL NO.		

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES (att. 2 refs.)
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET

RECEIVED
AUG 12 2003

TECH CENTER 1614/2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Neville J. Anthony, et al.


Serial No. 09/973,853

Filed: October 10, 2001

For: AZA- AND POLYAZA-NAPHTHALENYL
CARBOXAMIDES USEFUL AS INTEGRASE
INHIBITORS

Art Unit: 1614

Examiner: Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

DOCKETED
APR 24 2003
TECH CENTER

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By Markus Romero Date 4/23/03

INFORMATION DISCLOSURE STATEMENT

4. Except for Cite Nos. _____, copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.


Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3462

Date: April 23, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

D/F RECEIVED
AUG 12 2003
PATENT
TECH CENTER 10

Applicants:	Anthony et al.		
Serial No.:	09/973,853	Case No.:	20757Y
Filed:	October 10, 2001		
For:	AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS INTEGRASE INHIBITORS		

Art Unit:
1614

Examiner:
Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DOCKETED
JUL 15 2003
LORI SCHEPISI

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit the following information which they believe may be pertinent to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56:

PART A

Before the filing date of the instant application, the Istituto di Ricerche di Biologia Molecolare P. Angeletti S.P.A. (IRBM) located in Italy disclosed in confidence to certain Merck employees including one or more of the applicants of the instant application certain 5,6-dihydroxypyrimidine-4-carboxamides and suggested that these compounds might be


CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE APPEARING BELOW.






MERCK & CO., INC.


BY Christina Dona DATE: 7/15/03

active as HIV integrase inhibitors. Representative of the earliest compounds disclosed by IRBM are 2-thienyl-substituted compounds of Formula A:



wherein R is






IRBM conducted further research on the dihydroxypyrimidine carboxamide series of compounds which led to the filing of patent applications WO 03/35076 and WO 03/35077, each of which is cited in a Form 1449 accompanying this statement (see Part B below). IRBM periodically communicated in confidence to certain Merck employees including one or more of

the applicants of the instant application on the progress of their work leading up to these patent filings, and accordingly many, though not all, of the compounds described in WO 03/35076 and WO 03/35077 were known to the applicants before the filing date of the instant application.

Before the filing date of the instant application all of the compounds of Formula A specified above and many, though not all, of the compounds described in WO 03/35076 and WO 03/35077 were tested for HIV integrase inhibition activity at Merck in the United States after their preparation in Italy.

IRBM also disclosed in confidence before the filing date of the instant application certain dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors, especially as inhibitors of the hepatitis C virus polymerase enzyme. These compounds are described in WO 02/06246, which is cited in the accompanying Form 1449 (see Part B below). Many of these compounds were also tested for HIV integrase inhibiting activity at Merck in the United States before the filing date of the instant application.

IRBM also prepared the following two naphthyridine compounds before the filing date of the instant application:



The preparation of these compounds was communicated in confidence to certain Merck employees including one or more of the applicants of the instant application before its filing date. These compounds were tested in Italy against HCV polymerase and tested against HIV integrase at Merck in the United States before the filing date of the instant application.

The subject matter developed and disclosed by IRBM and the invention claimed in the instant application were not owned by the same person or subject to an obligation of assignment to the same person at the time the invention was made.

PART B

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached Form 1449 are citations to the following patent documents: US 6262055, US 6306891, US 6380249, WO

02/06246, WO 01/00578, WO 03/35076, and WO 03/35077. Copies of these documents are enclosed herewith.

PART C

U.S. Application Serial No. 10/260,029, filed June 6, 2003, is also brought to the Examiner's attention. This pending application corresponds to WO 01/00578 listed above. A copy of USSN 10/260,029 is enclosed herewith.

PART D

The subject matter disclosed and claimed in US 6306891, US 6380249, and USSN 10/260,029 was communicated in confidence to the applicants of the instant application before the filing date of the instant application. Subject matter contained in the above-cited US patents and applications and the invention claimed in the instant application were not owned by the same person or subject to an obligation of assignment to the same person at the time the invention was made.

The submissions in Parts A, B, C and D are not to be construed as admissions that any of the submitted information is "prior art" with respect to the claimed invention. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In addition, in accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information disclosed is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

It is requested that the Examiner consider the information set forth in Parts A, B, C and D and make it of record. It is further requested that the Examiner return an initialed copy of the attached form 1449 with the next communication to Applicants to signify that the statement has been considered and made of record.

This statement is being submitted more than three months after the filing of the instant application but before the mailing of the first Office Action on the merits. Accordingly, no fee is believed to be due.

Respectfully submitted,

By: Kenneth R. Walton

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: July 14, 2003



RECEIVED

AUG 12 2003

TECH. CENTER 1600/2900

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

7/14/2003

CASE NUMBER/

20757Y

SERIAL NUMBER

09/973,853

DATE FILED

October 10, 2001


APPLICANT

Anthony et al.

EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET





P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY

Kenneth R. Walton

DATE

4-23-03

CASE NUMBER/

20757Y

SERIAL NUMBER

09/973,853

DATE FILED

October 10, 2001


APPLICANT

Neville J. Anthony, et al

EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECT
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



F4424




EXHIBIT 2

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11 of 12

Applicants: Anthony et al.

Serial No.: 09/973,853

Case No.: 20757Y

Filed: October 10, 2001

For: Aza- and Polyaza-Napthalenyl Carboxamides Useful as
HIV Integrase Inhibitors

Art Unit:
1614

Examiner:
To Be Assigned

AUG 12 2003

RECEIVED
TECH CENTER 1600/2000
JAN 6 2002
BARBARA RE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants also wish to bring the following co-pending PCT applications designating the U.S. to the Examiner's attention.

~~Case 20758Y PCT - Appl'n No. PCT/US01/31550, filed 10/09/01 - Anthony et al.~~
~~Case 20759Y PCT - Appl'n No. PCT/US01/42505, filed 10/09/01 - Anthony et al.~~
~~Case 20760Y PCT - Appl'n No. PCT/US01/42553, filed 10/09/01 - Zhuang et al.~~


Copies of these applications are enclosed herewith. Applicants hereby request that Examiner consider the above-listed co-pending cases, initial beside each to indicate that the co-pending applications have, in fact, been considered, and return a copy of the initialed page to Applicants.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: January 11, 2002



THE UNITED STATES PATENT AND TRADEMARK OFFICE

12 of 12

PATENT

RECEIVED

AUG 12 2003

TECH CENTER 1000/2000

Applicants: Anthony et al.

Serial No.: 09/973,853

Case No.: 20757Y

Art Unit: DOCKETED

1614

FEB 12 2003

Filed: October 10, 2001

Examiner: LORI SCHEPISI

For: AZA- AND POLYAZA-NAPHTHALENYL
CARBOXAMIDES USEFUL AS INTEGRASE
INHIBITORS

Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to bring the following co-pending applications to the Examiner's attention.

BC	Case 20949Y	PCT Serial No. PCT/US 02/25666; Int'l Filing Date -- 13 Aug 2002	Merck & Co., Inc.
BC	Case 20950Y	PCT Serial No. PCT/US 02/27151; Int'l Filing Date -- 13 Aug 2002	Merck & Co., Inc.
BC	Case 20951Y	Serial No. 10/218,537, filed 14 Aug 2002	Anthony et al.

Applicants hereby request that Examiner consider the above-listed co-pending cases, initial beside each to indicate that the co-pending applications have, in fact, been considered, and return a copy of the initialed page to Applicants. Enclosed are copies of these applications as originally filed.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT February 12, 2003
EXPRESS MAIL NO. EL 920762522 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231.
MAILED BY LORI SCHEPISI
DATE 2-12-03

Respectfully submitted,

By:

Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: February 12, 2003